An update from Skye Bioscience ( ($SKYE) ) is now available. On December 18, 2025, Skye Bioscience, Inc. entered into a non-exclusive ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the ...

Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors ("GPCRs") to treat obesity, ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...

Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for nimacimab, describing the quarter as a "notable prelude to our reporting of our Phase IIa data for ...

Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) (“Skye”), a ...

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. Currently, Skye’s average price target ...

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ...

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule ...